All In Biotech

Drug Trial Radar · NCT06788990

FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC

A Multicenter, Randomized, Double-blind, Phase 2/3 Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab for First-Line Treatment of PD-L1-positive, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 650 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

650

Planned (sponsor's estimate)

Start

Jan 28, 2025

Primary completion

Apr 2028

Study completion Jul 2029

Sponsor

Lead sponsor
Bicara TherapeuticsIndustry
Sponsor type
Industry
First posted
Jan 23, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Ficerafusp alfa is directed against two targets, Epidermal Growth Factor Receptor (EGFR) and Transforming Growth Factor beta (TGF-β). This study intends to evaluate the safety and efficacy of ficerafusp alfa in combination with pembrolizumab versus placebo with pembrolizumab in 1L PD-L1-positive, recurrent or metastatic Head and Neck Squamous Cell Carcinoma (HNSCC).

Conditions

  • Metastatic Head and Neck Squamous Cell Carcinoma
  • Recurrent Head and Neck Squamous Cell Carcinoma

Interventions

  • Ficerafusp alfaDrug

    Investigational

  • Pembrolizumab (KEYTRUDA®)Drug

    Immunotherapy agent used in combination with investigational agent

  • PlaceboDrug

    Placebo Control

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 2 - Incidence and severity of TEAEs, treatment-treatment emergent SAEs TEAEs leading to dose interruption, dose reduction, or permanent discontinuation.Time frame: Up to 30 days post end of treatment for TEAEs (90 days for SAEs).
  2. Phase 2 - Objective Response Rate (ORR) per RECIST 1.1 by blinded independent central review (BICR)Time frame: Approximately 1 year.
  3. Phase 3 - Objective Response Rate (ORR) per RECIST 1.1 by BICR.Time frame: Approximately 2 years.
  4. Phase 3 - Overall Survival (OS)Time frame: Approximately 3 years.

Locations

242 sites in 28 countries. Site status is shown where the registry gives one.

  • University of Alabama Hospital (Site # 0137)

    Birmingham, Alabama · Recruiting

  • Mayo Clinic Hospital (Site #0147)

    Phoenix, Arizona · Recruiting

  • UC San Diego Moores Cancer Center (Site #0107)

    La Jolla, California · Recruiting

  • UCLA Department of Medicine - Hematology/Oncology (Site #0106)

    Los Angeles, California · Recruiting

  • UC Davis (Site#0144)

    Sacramento, California · Recruiting

  • University of California San Francisco (Site #0130)

    San Francisco, California · Recruiting

  • Stanford Cancer Institute (Site #0150)

    Stanford, California · Recruiting

  • Rocky Mountain Cancer Centers, LLP (Site #0122)

    Aurora, Colorado · Recruiting

  • Rocky Mountain Regional VAMC (Site #0124)

    Aurora, Colorado · Recruiting

  • University of Colorado Cancer Center (UCCC) - Anschutz Medical Campus (Site#0121)

    Aurora, Colorado · Recruiting

  • ChristianaCare Helen F. Graham Cancer Center and Research Institute (Site # 127)

    Newark, Delaware · Recruiting

  • Mayo Clinic Florida (Site #0148)

    Jacksonville, Florida · Recruiting

  • Cancer Care Centers of Brevard (Site #0136)

    Palm Bay, Florida · Recruiting

  • Moffit Cancer Center (Site #0105)

    Tampa, Florida · Recruiting

  • Captain James A Lovell Federal Health Care Center-VA North Chicago (Site # 133)

    Chicago, Illinois · Recruiting

  • Indiana University Simon Cancer Center (Site #0164)

    Indianapolis, Indiana · Recruiting

  • University of Iowa Hospitals & Clinics (Site#0140)

    Iowa City, Iowa · Recruiting

  • University of Kansas Medical Center Research Institute, Inc. (Site #0149)

    Westwood, Kansas · Recruiting

  • University of Kentucky, Markey Cancer Center (Site # 109)

    Lexington, Kentucky · Recruiting

  • Norton Cancer Institute (Site#0111)

    Louisville, Kentucky · Recruiting

  • The University of Louisville, James Graham Brown Cancer Center (Site#0115)

    Louisville, Kentucky · Recruiting

  • University of Maryland Medical Group (Site #0112)

    Baltimore, Maryland · Recruiting

  • Massachusetts General Hospital (Site #0131)

    Boston, Massachusetts · Recruiting

  • Dana-Farber Cancer Institute (Site#0101)

    Boston, Massachusetts · Recruiting

  • University of Michigan (Site # 161)

    Ann Arbor, Michigan · Recruiting

  • Minnesota Oncology Hematology, P.A. (Site #0156)

    Maplewood, Minnesota · Recruiting

  • Mayo Clinic Cancer Center - Rochester (Site #0146)

    Rochester, Minnesota · Recruiting

  • Washington University School of Medicine (Site #0114)

    St Louis, Missouri · Recruiting

  • Hackensack Meridian Health (Site # 119)

    Hackensack, New Jersey · Recruiting

  • Rutgers- Cancer Institute (Site #0145)

    Newark, New Jersey · Recruiting

  • Mount Sinai (Site #0155)

    New York, New York · Recruiting

  • Memorial Sloan Kettering Cancer Center (Site#0142)

    New York, New York · Recruiting

  • Duke University Health System (Site#0118)

    Durham, North Carolina · Recruiting

  • Mercy Hospital (Site#0154)

    Canton, Ohio · Recruiting

  • University of Cincinnati Cancer Institute (Site#0117)

    Cincinnati, Ohio · Recruiting

  • University Hospitals Seidman Cancer Center (Site #0151)

    Cleveland, Ohio · Recruiting

  • Cleveland Clinic (Site #0108)

    Cleveland, Ohio · Recruiting

  • Providence Portland Medical Center (Site #0113)

    Portland, Oregon · Recruiting

  • UPMC Hillman Cancer Center (Site #0103)

    Pittsburgh, Pennsylvania · Recruiting

  • VA Pittsburgh Healthcare System (Site #0123)

    Pittsburgh, Pennsylvania · Recruiting

Showing 40 of 242 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.